Page title
Search SAMHSA Publications and Digital Products
Store Facets Summary
Main page content
Drug Abuse Warning Network: Findings from Drug-Related Emergency Department Visits, 2021
Published: December 2022
An analysis of final 2021 DAWN data presents: (1) nationally representative weighted estimates, including percent and unadjusted rates per 100,000, for all drug-related emergency department (ED) visits, (2) nationally representative weighted estimates for the top five drugs in drug-related ED visits, (3) the assessment of monthly trends and drugs involved in polysubstance ED visits in a subset of sentinel hospitals, and (4) the identification of drugs new to DAWN’s Drug Reference Vocabulary.Preliminary Findings from Drug-Related Emergency Department Visits, 2021: Results from the Drug Abuse Warning Network
Published: May 2022
An analysis of 2021 preliminary data presents (1) nationally representative weighted estimates for the top five drugs in drug-related ED visits, (2) the assessment of monthly trends and drugs involved in polysubstance ED visits in a subset of sentinel hospitals, and (3) the identification of drugs new to DAWN’s Drug Reference Vocabulary.Routine Administration of Cognitive Behavioral Therapy for Psychosis as the Standard of Care for Individuals Seeking Treatment for Psychosis
Published: May 2021
This guide provides mental health decision-makers (e.g., state/local mental health directors, treatment facility clinical directors, and other stakeholders) with rationale and evidence to support wide-spread expansion of Cognitive Behavioral Therapy for Psychosis (CBTp) across mental health systems.Behavioral Health Spending & Use Accounts, 2006-2015
Published: February 2019
This report provides updated estimates of mental health and substance use disorder spending by payment source and provider, setting, payer and specialty type. The report highlights spending on behavioral health by private insurers, Medicaid and Medicare as well as other payers.Medicaid Coverage of Medication-Assisted Treatment for Alcohol and Opioid Use Disorders and of Medication for the Reversal of Opioid Overdose
Published: November 2018
The report discusses Medicaid coverage of FDA-approved medications for treatment of alcohol and opioid use disorders, limitations on coverage (such as prior authorization requirements), background on federal laws and policies and innovative practices and policies at the state level.